The text provides recommendations for adjuvant treatments for stage I and II colorectal cancer. It suggests no adjuvant treatment for stage I, and for stage II, it recommends considering chemotherapy for patients without comorbidities, in good general health, and without DPD deficiency. It also mentions the importance of evaluating the balance of benefits and risks for each individual patient.